Search Within

Eileen O'Reilly

Formats
  1. Meeting Abstract (370)
  2. Journal Article (365)
  3. Review (24)
  4. Book Section (9)
  5. Correspondence (9)
  6. Editorial (8)
  7. Conference Paper (5)
  8. Miscellaneous (5)
  9. Book Whole (4)
  10. Guidelines (3)
  11. Research Letter (1)
Groups
  1. Center for Pancreatic Cancer Research (803)
  2. Department of Medicine (803)
  3. Gastrointestinal Oncology Service (803)
  4. Solid Tumor Oncology Division (803)
  5. Epidemiology and Biostatistics (184)
  6. Surgery (173)

More Groups

People
  1. Ghassan Abou-Alfa (160)
  2. Kenneth Yu (123)
  3. David Kelsen (112)
  4. Maeve Lowery (99)
  5. Marinela Capanu (97)
  6. William Jarnagin (88)

More People

Years
  1. 2025 (50)
  2. 2024 (76)
  3. 2023 (73)
  4. 2022 (57)
  5. 2021 (54)
  6. 2020 (70)

More Years

Publications
  1. Journal of Clinical Oncology (296)
  2. Annals of Oncology (51)
  3. Cancer (28)
  4. Annals of Surgical Oncology (26)
  5. Clinical Cancer Research (23)
  6. Gastrointestinal Cancer Research (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (312)
  2. Oxford University Press (75)
  3. Elsevier Inc. (49)
  4. Springer (47)
  5. Wiley Blackwell (43)
  6. American Association for Cancer Research (40)

More Publishers

Results (803)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Bhattacharya, P. P.; Moran, D. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo-Cid, R.; Chandana, S. R.; De La Fouchardiere, C.; Dean, Andrew P.; Kiss, I.; Lee, W.; Goetze, T. O.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC)
    Meeting Abstract

    Lyman, J. P.; Cabanski, C. R.; Maddock, S.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Rahma, O. E.; Fisher, G. A.; Gabriel, P. E.; Doucette, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC)
    Meeting Abstract

    Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO)
    Meeting Abstract

    Keane, F.; Balogun, F.; O'Connor, C.; Crowley, F.; Chan, A.; Cowzer, D.; Chou, J. F.; Park, W.; Varghese, A. M.; Yu, K. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer
    Meeting Abstract

    Reyngold, M.; Wei, A.; O'Reilly, E. M.; D'Angelica, M. I.; Drebin, J. A.; Soares, K.; Kingham, T. P.; Balachandran, V. P.; Varghese, A. M.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy
    Meeting Abstract

    Cowzer, D.; Huq, R.; Perry, M.; Keane, F.; Park, W.; El Dika, I. H.; Khalil, D.; Shia, J.; Sigel, C. S.; Bandlamudi, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes
    Journal Article

    Gu, L.; Mehta, P. P.; Rao, D.; Rotemberg, V.; Capanu, M.; Chou, J.; Lin, S.; Sigel, C. S.; Busam, K. J.; Boyce, L.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save
  • Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405
    Journal Article

    Van Blarigan, E. L.; Ma, C.; Ou, F. S.; Bainter, T. M.; Venook, A. P.; Ng, K.; Niedzwiecki, D.; Giovannucci, E.; Lenz, H. J.; Polite, B. N.; more...
    International Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Homologous recombination deficiency in pancreatic cancer: Poly (ADP-ribose) polymerase inhibition, checkpoint inhibition, or a combination of both?
    Correspondence

    Keane, F.; Park, W.; O'Reilly, E. M.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save